Autoantibodies and Sjogren's Syndrome in Multiple Sclerosis, a Reappraisal

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Solomon, Andrew J ^a   Hills, William ^b,c   Chen, Zunqiu ^b   Rosenbaum, James ^b   Bourdette, Dennis ^c,d   Whitham, Ruth ^c,d  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; LA ANTIBODY; RHEUMATOID FACTOR; RO ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; SJOEGREN SYNDROME;

AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MULTIPLE SCLEROSIS; OREGON; SJOGREN'S SYNDROME;

EID: 84878918490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065385     Document Type: Article

References (38)

1. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, et al. (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14: 1157-74.
2. Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, et al. (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 83: 280-91.
3. de Andrés C, Guillem A, Rodríguez-Mahou M, López Longo FJ, (2001) Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients. Acta Neurol Scand 104: 83-7.
4. Collard RC, Koehler RP, Mattson DH, (1997) Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 49: 857-61.
5. Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, et al. (2007) Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 187: 159-65.
6. Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, et al. (2002) Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry 72: 647-9.
7. Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, et al. (2000) Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 14: 259-65.
8. Stosic M, Ambrus J, Garg N, Weinstock-Guttman B, Ramanathan M, et al. (2010) MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol. 257: 63-71.
9. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, et al. (1998) Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 55: 517-21.
10. Vilisaar J, Wilson M, Niepel G, Blumhardt LD, Constantinescu CS, (2005) A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. Mult Scler 11: 378-80.
11. Chapman J, (2004) The interface of multiple sclerosis and antiphospholipid antibodies. Thromb Res 114: 477-81.
12. Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, Gruszka E, Korman L, et al. (2012) Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 21: 412-20.
13. Sastre-Garriga J, Reverter JC, Font J, Tintoré M, Espinosa G, et al. (2001) Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol 49: 408-11.
14. Karussis D, Leker RR, Ashkenazi A, Abramsky O, (1998) A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 44: 629-34.
15. Spadaro M, Amendolea MA, Mazzuconi MG, Fantozzi R, Di Lello R, et al. (1999) Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 5: 121-5.
16. Barned S, Goodman AD, Mattson DH, (1995) Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology 45: 384-5.
17. D'Olhaberriague L, Levine SR, Salowich-Palm L, Tanne D, Sawaya KL, et al. (1998) Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology 51: 1376-80.
18. Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB, (1982) Antinuclear antibodies in multiple sclerosis. Arch Neurol 39: 504-506.
19. De Keyser J, (1998) Autoimmunity in multiple sclerosis. Neurology 38: 371-374.
20. Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, et al. (2002) in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 22: 245-255.
21. Seyfert S, Klapps P, Meisel C, Fischer T, Junghan U, (1990) Multiple sclerosis and other immunologic diseases. Acta Neurol Scan 81: 37-42.
22. Ciccarelli O, Bagnato F, Mainero C, Salvetti M, Paolillo A, et al. (2000) Antinuclear antibodies and response to IFN-b therapy in relapsing-remitting multiple sclerosis. Mult Scler 6: 137-139.
23. de Seze J, Devos D, Castelnovo G, Labauge P, Dubucquoi S, et al. (2001) The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology 57: 1359-63.
24. Liedorp M, Sanchez E, van Hoogstraten IM, von Blomberg BM, Barkhof F, et al. (2007) No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg 78: 1146-8.
25. Pericot I, Brieva L, Tintoré M, Río J, Sastre-Garriga J, et al. (2003) Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler 9: 256-9.
26. Sandberg-Wollheim M, Axéll T, Hansen BU, Henricsson V, Ingesson E, et al. (1992) Primary Sjogren's syndrome in patients with multiple sclerosis. Neurology 42: 845-7.
27. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, et al. (2002) European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-8.
28. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302.
29. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG, (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-9.
30. Wingerchuk DM, Weinshenker BG, (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 18: 5-10.
31. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-6.
32. Bowen J, Gibbons L, Gianas A, Kraft GH, (2001) Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler 7: 201-6.
33. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, et al. (1997) Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40: 1601-11.
34. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN, (1990) Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med20: 231-6.
35. Vila P, Hernández MC, López-Fernández MF, Batlle J, (1994) Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72: 209-13.
36. Petri M, (2000) Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 15: 145-51.
37. Noseworthy JH, Bass BH, Vandervoort MK, Ebers GC, Rice GP, et al. (1989) The prevalence of primary Sjogren's syndrome in a multiple sclerosis population. Ann Neurol 25: 95-8.
38. Sánchez-Guerrero J, Pérez-Dosal MR, Celis-Aguilar E, Cárdenas-Velázquez F, Soto-Rojas AE, et al. (2006) Validity of screening tests for Sjogren's syndrome in ambulatory patients with chronic diseases. J Rheumatol 33: 907-11.